Published in Clin Diagn Lab Immunol on October 01, 2005
Diagnosis of visceral leishmaniasis: developments over the last decade. Parasitol Res (2011) 1.21
Towards a more precise serological diagnosis of human tegumentary leishmaniasis using Leishmania recombinant proteins. PLoS One (2013) 0.92
Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis. Clin Vaccine Immunol (2006) 0.88
Development of a fluorescent based immunosensor for the serodiagnosis of canine leishmaniasis combining immunomagnetic separation and flow cytometry. PLoS Negl Trop Dis (2013) 0.79
Detection of anti-leishmania (Leishmania) chagasi immunoglobulin G by flow cytometry for cure assessment following chemotherapeutic treatment of American visceral leishmaniasis. Clin Vaccine Immunol (2007) 0.78
Dynamics and predictive potential of antibodies against insect-derived recombinant Leishmania infantum proteins during chemotherapy of naturally infected dogs. Am J Trop Med Hyg (2010) 0.77
The Leishmania infantum PUF proteins are targets of the humoral response during visceral leishmaniasis. BMC Res Notes (2010) 0.76
Detection of IgG Anti-Leishmania Antigen by Flow Cytometry as a Diagnostic Test for Cutaneous Leishmaniasis. PLoS One (2016) 0.75
Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrob Agents Chemother (2014) 0.75
Multi-antigen print immunoassay (MAPIA)-based evaluation of novel recombinant Leishmania infantum antigens for the serodiagnosis of canine visceral leishmaniasis. Parasit Vectors (2015) 0.75
Application of Recombinant Proteins for Serodiagnosis of Visceral Leishmaniasis in Humans and Dogs. Iran Biomed J (2016) 0.75
Synthetic Peptides as Potential Antigens for Cutaneous Leishmaniosis Diagnosis. J Immunol Res (2017) 0.75
The concurrent occurrence of Leishmania chagasi infection and childhood acute leukemia in Brazil. Rev Bras Hematol Hemoter (2014) 0.75
Evaluation of an enzyme-linked immunosorbent assay based on crude Leishmania histone proteins for serodiagnosis of human infantile visceral leishmaniasis. Clin Vaccine Immunol (2012) 0.75
Leishmaniasis. Public health aspects and control. Clin Dermatol (1997) 4.77
Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest (1985) 3.41
A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med (2005) 2.50
Epidemiology of visceral leishmaniasis in northeast Brazil. J Infect Dis (1992) 1.99
Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis (1992) 1.90
Visceral leishmaniasis control: a public health perspective. Trans R Soc Trop Med Hyg (2000) 1.46
The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am J Trop Med Hyg (2002) 1.43
Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis. J Clin Microbiol (1998) 1.13
Diagnosis of leishmaniasis. Clin Dermatol (1997) 1.02
Calcium-induced conformational changes in Leishmania infantum kinetoplastid membrane protein-11. J Biol Inorg Chem (2001) 0.88
The treatment of kala-azar: old and new options. Trop Geogr Med (1992) 0.86
Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest (1985) 3.41
New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92
Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun (1981) 2.88
Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med (1990) 2.67
Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol (2001) 2.56
Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis (1996) 2.42
A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis (1986) 2.24
Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol (1985) 2.24
Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res (1998) 1.99
Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg (1986) 1.93
Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem (2003) 1.81
A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med (1995) 1.81
A pilot experience with permanent biventricular pacing to treat advanced heart failure. Am Heart J (2000) 1.78
Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis. Infect Immun (2004) 1.72
Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg (1991) 1.71
Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria. Cell Death Differ (2001) 1.69
Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev (2000) 1.68
Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg (2001) 1.65
Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, Brazil. Trans R Soc Trop Med Hyg (2009) 1.63
MOM-4, a MAP kinase kinase kinase-related protein, activates WRM-1/LIT-1 kinase to transduce anterior/posterior polarity signals in C. elegans. Mol Cell (1999) 1.56
Oral nifedipine vs oral clonidine in the treatment of urgent hypertension. Arch Intern Med (1989) 1.54
Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis. J Infect Dis (1999) 1.53
Enhanced helminthotoxic capacity of eosinophils from patients with eosinophilia. N Engl J Med (1980) 1.50
Inverse association between skin response to aeroallergens and Schistosoma mansoni infection. Int Arch Allergy Immunol (2000) 1.49
Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. J Trop Med Hyg (1986) 1.48
IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine (2000) 1.47
A head-to-tail tandem organization of hsp70 genes in Trypanosoma cruzi. Nucleic Acids Res (1988) 1.47
Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med (1990) 1.43
Recruitment of CD8(+) T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis. Parasite Immunol (2009) 1.43
Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer. J Nucl Med (1990) 1.42
Leishmania donovani: an opportunistic microbe associated with progressive disease in three immunocompromised patients. Lancet (1986) 1.42
Circulating immune complexes and rheumatoid factor in schistosomiasis and visceral leishmaniasis. Am J Trop Med Hyg (1983) 1.38
Echocardiographic modeling of cardiac dyssynchrony before and during multisite stimulation: a prospective study. Pacing Clin Electrophysiol (2003) 1.38
Characterization of a non-long terminal repeat retrotransposon cDNA (L1Tc) from Trypanosoma cruzi: homology of the first ORF with the ape family of DNA repair enzymes. J Mol Biol (1995) 1.36
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat (2001) 1.36
Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological forms of two Leishmania species. Am J Trop Med Hyg (1983) 1.32
3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res (1998) 1.31
Immune and clinical parameters associated with Leishmania infantum infection in the golden hamster model. Vet Immunol Immunopathol (2000) 1.29
Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis (1991) 1.29
Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J Infect Dis (1996) 1.29
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat (2009) 1.25
HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis. Parasite Immunol (2001) 1.25
Mucosal leishmaniasis patients display an activated inflammatory T-cell phenotype associated with a nonbalanced monocyte population. Scand J Immunol (2006) 1.24
Evaluation of the micro enzyme-linked immunosorbent assay (ELISA) for antibodies in American visceral leishmaniasis: antigen selection for detection of infection-specific responses. Am J Trop Med Hyg (1986) 1.24
Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis. Am J Trop Med Hyg (1995) 1.24
Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol Today (2000) 1.21
Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun (1995) 1.20
Analysis of post-transcriptional regulation operating on transcription products of the tandemly linked Leishmania infantum hsp70 genes. J Biol Chem (1997) 1.19
Interferon-gamma and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis. J Infect Dis (1998) 1.17
Do non-long terminal repeat retrotransposons have nuclease activity? Trends Biochem Sci (1996) 1.17
The role of charged amphipathic helices in the structure and function of surfactant protein B. J Pept Res (2005) 1.16
Evidence of a T helper type 2 activation in human schistosomiasis. Eur J Immunol (1996) 1.16
Biological behavior of Leishmania amazonensis isolated from humans with cutaneous, mucosal, or visceral leishmaniasis in BALB/C mice. Am J Trop Med Hyg (1996) 1.16
Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol (1995) 1.15
Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res (2012) 1.14
Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis. J Clin Microbiol (1998) 1.13
Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol (1991) 1.12
Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect Immun (2000) 1.12
The African swine fever virus proteins p54 and p30 are involved in two distinct steps of virus attachment and both contribute to the antibody-mediated protective immune response. Virology (1998) 1.11
African swine fever virus gene A179L, a viral homologue of bcl-2, protects cells from programmed cell death. Virology (1996) 1.10
Neutralizing antibodies to different proteins of African swine fever virus inhibit both virus attachment and internalization. J Virol (1996) 1.10
Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. Int J Dermatol (1995) 1.10
Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol (1991) 1.09
Characterization of a membrane antigen of Leishmania amazonensis that stimulates human immune responses. J Immunol (1991) 1.09
In situ hybridization of nuclear and cytoplasmic RNA to locus 2-48BC in Drosophila hydei. Chromosoma (1978) 1.08
Variation of cytokine patterns related to therapeutic response in diffuse cutaneous leishmaniasis. Exp Parasitol (1996) 1.08
Genomic organization and expression of two independent gene arrays coding for two antigenic acidic ribosomal proteins of Leishmania. J Biol Chem (1993) 1.08
Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83. Mol Immunol (1999) 1.07
IL-17 and Regulatory Cytokines (IL-10 and IL-27) in L. braziliensis Infection. Parasite Immunol (2011) 1.07
Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice. Infect Immun (1998) 1.06
Optimization and validation of recombinant serological tests for African Swine Fever diagnosis based on detection of the p30 protein produced in Trichoplusia ni larvae. J Clin Microbiol (2006) 1.06
Characterization and molecular basis of heterogeneity of the African swine fever virus envelope protein p54. J Virol (1994) 1.06
Effect of okadaic acid on O-linked N-acetylglucosamine levels in a neuroblastoma cell line. Biochim Biophys Acta (1999) 1.06
Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Pathol (1995) 1.05
Evaluation of cefamandole therapy of patients with bacterial meningitis. J Infect Dis (1978) 1.03
Bacterial infections in patients with visceral leishmaniasis. J Infect Dis (1990) 1.03
Z-DNA in transcriptionally active chromosomes. Proc Natl Acad Sci U S A (1987) 1.03
Binuclear chloro-bridged palladated and platinated complexes derived from p-isopropylbenzaldehyde thiosemicarbazone with cytotoxicity against cisplatin resistant tumor cell lines. J Inorg Biochem (1998) 1.03
Schistosoma mansoni antigens modulate the allergic response in a murine model of ovalbumin-induced airway inflammation. Clin Exp Immunol (2010) 1.02
Identification of a putative regulatory element in the 3'-untranslated region that controls expression of HSP70 in Leishmania infantum. Mol Biochem Parasitol (2000) 1.02
DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect Immun (2001) 1.02
Conditions required for Fc-dependent immune complex enhancement of antigen-specific lymphocyte blastogenesis. J Immunol (1980) 1.02
A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Hum Mutat (2006) 1.02
The open reading frame 1 of the L1Tc retrotransposon of Trypanosoma cruzi codes for a protein with apurinic-apyrimidinic nuclease activity. J Biol Chem (1997) 1.01
Characterization of Le(x), Le(y) and A Le(y) antigen determinants in KDN-containing O-linked glycan chains from Pleurodeles waltlii jelly coat eggs. FEBS Lett (1992) 1.00
High HTLV-1 proviral load, a marker for HTLV-1 associated myelopathy/tropical spastic paraparesis, is also detected in patients with infective dermatitis associated with HTLV-1. Braz J Med Biol Res (2009) 1.00
Immunohistological features of visceral leishmaniasis in BALB/c mice. Parasite Immunol (2006) 1.00
Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis. Immunol Lett (1995) 1.00
Suppression of lymphocyte proliferative responses by sera from patients with American visceral leishmaniasis. Am J Trop Med Hyg (1986) 0.99
Mapping human T cell epitopes in leishmania gp63. Identification of cross-reactive and species-specific epitopes. J Immunol (1993) 0.99
Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis. Mem Inst Oswaldo Cruz (1998) 0.98